of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Termination of a Material Definitive Agreement. On June 2, 2026, the parties terminated the Prior Credit Agreement in connection with the Borrower’s prepayment in full of all outstanding borrowings and accrued interest thereunder.

Entry into a Material Definitive Agreement. On June 2, 2026, Maravai Intermediate Holdings, LLC (the “Borrower”) and Maravai Topco Holdings, LLC (“Topco”), each a consolidated subsidiary controlled by Maravai LifeSciences Holdings, Inc., entered into a Credit Agreement (the “New Credit Agreement”) with certain lenders and issuing banks party thereto and BSP Agency, LLC, as administrative agent and collateral agent. The New Credit Agreement provides the Borrower with a $150.0 million term loan…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet arrangement of a Registrant. The information set forth above in

of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Director — Benjamin Daverman, Jessica Hopfield, PhD, Murali Prahalad, PhD: Three directors resigned as part of the company's efforts to rationalize the size of its Board and reduce administrative costs.

Executive Vice President and Chief Commercial Officer / Executive Vice President and Chief Administrative Officer — Rebecca Buzzeo, Pete Leddy, Ph.D.: The positions of Rebecca Buzzeo and Pete Leddy were eliminated by the Board, resulting in their termination without cause.

Costs Associated with Exit or Disposal Activities. On August 11, 2025, the Company announced an organizational restructuring, including a workforce reduction, to reduce operating costs. The workforce reduction, which is being implemented as part of a strategic cost-reduction initiative, was committed to by management on August 8, 2025 and is expected to impact approximately 25% of the Company’s workforce. In connection with the workforce reduction, the Company currently estimates it will incu…

of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Changes in Registrant’s Certifying Accountant. On July 16, 2025 (the “ Approval Dat e”), the Audit Committee (the “ Audit Committee ”) of the Board of Directors of Maravai LifeSciences Holdings, Inc. (the “ Company ”) approved the appointment of Deloitte & Touche LLP (“ Deloitte ”) as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025, effective immediately. In addition, on the Approval Date, the Audit Committee approved the dismissa…

Chief Financial Officer — Rajesh Asarpota: Mr. Rajesh Asarpota was appointed as the new Chief Financial Officer, succeeding Kevin Herde.

CEO — William E. Martin, III: William E. Martin, III resigned as CEO and from the Board, succeeded by Bernd Brust.

of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking statements” within the meanin…

of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. (a) On March 17, 2025, the Audit Committee of the Board of Directors of the Company (the “Audit Committee”) concluded that the Company’s interim financial statements and related disclosures included in the Company’s Quarterly Reports on Form 10-Q for the fiscal quarters ended June 30, 2024 (“Q2 2024”), and September 30, 2024 (“Q3 2024”), and as of and for the interim periods ended Jun…

Results of Operations and Financial Condition. On February 25, 2025, Maravai LifeSciences Holdings, Inc. (the “Company”) issued a press release (the “February 2025 Press Release”) announcing, among other things, that it will be delaying its earnings release and call previously scheduled for February 25, 2025, because it requires additional time to complete its financial close process. The Company intends to file a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange…

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

President, Nucleic Acid Production — Andrew Burch: Mr. Burch's position was eliminated to flatten the organizational structure.

Other Events. On December 18, 2024, Maravai Intermediate Holdings, LLC (“Maravai Intermediate”), a subsidiary of Maravai LifeSciences Holdings, Inc., voluntarily pre-paid, using cash on hand, $228 million of aggregate principal amount of the outstanding term loan (the “Term Loan”) provided under the previously disclosed Credit Agreement, dated as of October 19, 2020, among Maravai Intermediate, Cygnus Technologies, LLC (“Cygnus”), TriLink Biotechnologies, LLC (“TriLink” and together with Mara…

Executive Chairman of the Board — Carl Hull: Carl Hull retired as Executive Chairman and Robert Andrew Eckert was appointed as the new Chairman of the Board.

of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Entry into a Material Definitive Agreement On September 10, 2024, we amended our Existing Credit Agreement (as defined below), enabling us to extend the maturity date of our revolving credit facility by five years (subject to springing maturity provisions based on the maturity of the term loan facility which currently matures in October 2027), upon satisfaction of customary closing conditions including the payment of a commitment fee of 0.65% of the $167M revolving facility. Our revolving cre…